Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
Telehealth Autism Care Access Study, University of Minnesota
Telehealth Autism Care Access Study, University of Minnesota
ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
The USPTO published patent application US20260098078A1 covering activin receptor type II chimera polypeptides for treating conditions involving muscle weakness and atrophy, bone damage, blood disorders such as anemia, thrombocytopenia, and neutropenia, as well as fibrosis, metabolic disorders, and pulmonary hypertension. The application describes extracellular ActRII chimeras optionally fused to Fc domains as therapeutic agents.
Cμ4 Region for Multi-Specific Antibody Chain Pairing
USPTO published patent application US20260098094A1 assigned to DNA Twopointo, Inc. covering multi-specific antibodies with IgM Cμ4 region pairing domains for correct heavy and light chain pairing. The invention promotes correct chain combinations and disfavors incorrect pairings in bispecific antibodies. The application was filed November 21, 2025.
HIV/HBV Treatment Using CD8-Targeting Fusion Proteins
USPTO published patent application US20260098090A1 on April 9, 2026, disclosing fusion proteins for treating chronic viral infections including HIV and HBV. The application describes methods using CD8-targeting fusion proteins comprising antibodies specific to CD8b or CD8ab antigens combined with cytokines, chemokines, or growth factors. Inventors are Kelly Dare Moynihan, Yik Andy Yeung, and Ivana Djuretic, with filing date September 28, 2023.
CD7 Antibody Antagonists for Therapeutic Applications
USPTO published patent application US20260098089A1 titled 'CD7 Antibody Antagonists for Therapeutic Applications' filed September 8, 2025 by inventors E-Chiang Lee, Gwenoline Borhis, Cassandra Van Krinks, Lucy Hepburn, Luke Bayliss, and Miha Kosmac. The application covers Cluster of Differentiation 7 (CD7) antibody antagonists and fragments for therapeutic uses, including methods, uses, and combinations. Patent applications establish priority dates and filing status but do not yet grant enforceable intellectual property rights.
Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis US20260098088A1
USPTO published patent application US20260098088A1 assigned to Disc Medicine, Inc. The application covers anti-hemojuvelin (HJV) antibodies and methods for treating myelofibrosis and associated conditions. Inventors include Maria Beconi, John Quisel, Brian MacDonald, Steven Robinette, Bernhard Mueller, Andreas Popp, and Jennifer M. Perez. CPC classifications include C07K 16/28 and related antibody technology classes.
Anti-CGRP Monoclonal Antibodies for Treating Nausea and Vomiting Including CINV
The USPTO published patent application US20260098082A1 for methods using anti-Calcitonin gene related peptide (CGRP) monoclonal antibodies to treat nausea and vomiting, including chemotherapy-induced nausea and vomiting (CINV). The application, filed September 13, 2023, claims methods of preventing and counteracting CINV by targeting CGRP, a neuropeptide associated with emetic responses to chemotherapy and other triggers.
Modified Protein Scaffold Patent by Evolveritas
The USPTO published patent application US20260098080A1 for a modified protein scaffold comprising amino acid sequence SEQ ID NO: 115 with specific amino acid modifications in defined positions. The application was filed by Evolveritas Biotechnológiai Korlátolt Felelősségű Társaság, a Hungarian biotechnology company, with eight named inventors. The claimed protein scaffold includes segment formula Ih-mod GX1CX1VX2X3X4X5 and is intended for pharmaceutical preparations, kits, and screening procedures.
High-Purity Recombinant Human Albumin Preparation Method
Tonghua Anrate Biopharmaceutical Co., Ltd. has filed USPTO Patent Application US20260098079A1 for a method of preparing high-purity recombinant human albumin using medium-long-chain fatty acid ligands and ion exchange chromatography. The application discloses a process where oleic acid, myristic acid, sodium palmitate, and sodium stearate are combined with recombinant human albumin in defined molar ratios with poloxamer to achieve high stability and purity through sequential anion and/or cation chromatography to remove truncated and modified albumins.
Protein Crystallization Method, Multiple Protein Feeds
Protein Crystallization Method, Multiple Protein Feeds
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
661 changes in last 7 days
Latest high priority updates
142 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.